Pfizer Inc
- Industry
- Pharmaceuticals
- Exchange
- US
- Country
- USA
- IPO date
- Jun 22, 1942
- Employees
- 75,000
- Website
- www.pfizer.com
Composite valuation range · conservative $16–$19 / fair $24–$28 / optimistic $32–$36. At $24.67, Within the fair intrinsic-value range.
At publication $25.85 (May 25, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
History
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. The company went public with an IPO date of June 22, 1942. In recent years it has expanded through external dealmaking: the Seagen acquisition was consolidated in 2023 (lifting total debt to about $70.84B that year), and in 2025 it agreed to acquire Metsera, funding that deal alongside refinancing and general purposes with roughly $9.7B of newly issued USD and EUR debt. Other named transactions include Biohaven and 3SBio. In Q1 2026 a patent settlement for Vyndamax extended the product's effective U.S. patent term to June 1, 2031.
Industry position
Pfizer is a global biopharmaceutical company operating in three segments—Biopharma, PC1, and Pfizer Ignite—with about 75,000 employees. 2025 revenue was $62.58B, with the top ten products contributing roughly $38.3B, about 60% of the total; leading products included Eliquis ($7.961B), the Prevnar family ($6.494B), the Vyndaqel family ($6.380B), Comirnaty ($4.367B), and Ibrance ($4.122B). Its portfolio spans internal medicine, vaccines, oncology, inflammation & immunology, rare disease, and biosimilars. Pfizer invested about $10.4B in internal R&D in 2025 and names AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Roche, and Sanofi as principal pharmaceutical peers.